Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who are reasonably active and able to care for themselves (as assessed by a standard medical scale called ECOG Performance Status 0–2), and who are expected to live for at least 3 months.
• People who have a confirmed cancer that has spread to the brain, with 1 to 5 tumours located within the brain tissue, as shown on a special type of MRI scan using contrast dye.
• People whose brain tumours are well-defined and measurable in size — each tumour must be no larger than 3.0 cm across, and at least one tumour must meet minimum size requirements to be considered measurable (confirm with trial site for exact measurements).
• Women who could potentially become pregnant must have had a negative pregnancy test (urine or blood) within 14 days before a planning scan called CT simulation.
• People who are able to understand the trial information and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

• People whose cancer is a germ cell tumour, small cell carcinoma, or a blood cancer (such as leukaemia or lymphoma).
• People whose brain tumours are located in certain sensitive areas of the brain — specifically the brain stem, midbrain, pons, medulla — or within 7 mm of the optic nerves, optic chiasm, or optic tracts (the parts of the brain involved in vision).
• People who have been diagnosed with leptomeningeal disease, meaning cancer has spread to the lining around the brain and spinal cord.
• People who have had radiation treatment to the brain within 90 days before joining the trial, or who have previously had a type of targeted radiation treatment (called stereotactic radiosurgery, or SRS) to any of the specific lesions that would be treated in this trial.
• People who have received certain cancer treatments — including chemotherapy, targeted therapy, or immunotherapy — within 14 days before the planned radiation treatment; people with a type of breast cancer called HER2+ who have received anti-HER2 therapy within 14 days before treatment; or people scheduled to receive a specific drug called trastuzumab emtansine after the radiation treatment. Hormone therapy is permitted.
• People who cannot safely have an MRI scan with contrast dye — for example, those with a non-compatible pacemaker, severely reduced kidney function, or a known allergy to the contrast dye used (gadolinium).

Important: Always verify eligibility with the trial site directly before applying.